Xenon Pharmaceuticals Inc
XENE32.590USD
+2.090+6.85%
Horário de mercado （ET）Cotações atrasadas em 15 min
2.50BValor de mercado
PerdaP/L TTM
Mais detalhes de Xenon Pharmaceuticals Inc Empresa
Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, the Company's lead Kv7 channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. Azetukalner is being developed for the treatment of epilepsy, including focal onset seizures (FOS) and primary generalized tonic-clonic seizures (PGTCS) as well as major depressive disorder (MDD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications. It has an ongoing collaboration with Neurocrine Biosciences, Inc. to develop treatments for epilepsy.
Informações da empresa
Código da empresaXENE
Nome da EmpresaXenon Pharmaceuticals Inc
Data de listagemOct 17, 2014
CEOMr. Ian C. Mortimer, CPA
Número de funcionários316
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 17
Endereço3650 Gilmore Way
CidadeVANCOUVER
Bolsa de valoresNASDAQ Global Market Consolidated
PaísCanada
Código postalV5G 4W8
Telefone16044843300
Sitehttps://www.xenon-pharma.com/
Código da empresaXENE
Data de listagemOct 17, 2014
CEOMr. Ian C. Mortimer, CPA
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Ian C. Mortimer, CPA
Mr. Ian C. Mortimer, CPA
President, Chief Executive Officer, Interim Chief Financial Officer, Director
President, Chief Executive Officer, Interim Chief Financial Officer, Director
45.60K
--
Dr. Gary Patou, M.D.
Dr. Gary Patou, M.D.
Independent Director
Independent Director
28.48K
--
Ms. Dawn A. (Graham) Svoronos
Ms. Dawn A. (Graham) Svoronos
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
25.00K
--
Mr. Steven R. (Steve) Gannon, CPA
Mr. Steven R. (Steve) Gannon, CPA
Independent Director
Independent Director
7.14K
-0.04%
Dr. Christopher Kenney, M.D.
Dr. Christopher Kenney, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Darren S. Cline
Mr. Darren S. Cline
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Patrick Machado, J.D.
Mr. Patrick Machado, J.D.
Independent Director
Independent Director
--
--
Dr. Gillian M. Cannon, Ph.D.
Dr. Gillian M. Cannon, Ph.D.
Independent Director
Independent Director
--
--
Mr. Justin Gover
Mr. Justin Gover
Independent Director
Independent Director
--
--
Ms. Andrea Marie Difabio, J.D.
Ms. Andrea Marie Difabio, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Ian C. Mortimer, CPA
Mr. Ian C. Mortimer, CPA
President, Chief Executive Officer, Interim Chief Financial Officer, Director
President, Chief Executive Officer, Interim Chief Financial Officer, Director
45.60K
--
Dr. Gary Patou, M.D.
Dr. Gary Patou, M.D.
Independent Director
Independent Director
28.48K
--
Ms. Dawn A. (Graham) Svoronos
Ms. Dawn A. (Graham) Svoronos
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
25.00K
--
Mr. Steven R. (Steve) Gannon, CPA
Mr. Steven R. (Steve) Gannon, CPA
Independent Director
Independent Director
7.14K
-0.04%
Dr. Christopher Kenney, M.D.
Dr. Christopher Kenney, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Darren S. Cline
Mr. Darren S. Cline
Chief Commercial Officer
Chief Commercial Officer
--
--
Detalhamento da receita
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
Canada
7.50M
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: dom, 3 de ago
Atualizado em: dom, 3 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Fidelity Management & Research Company LLC
8.03%
Avoro Capital Advisors LLC
7.48%
Driehaus Capital Management, LLC
5.97%
Wellington Management Company, LLP
4.94%
Janus Henderson Investors
4.33%
Other
69.25%
Investidores
Investidores
Proporção
Fidelity Management & Research Company LLC
8.03%
Avoro Capital Advisors LLC
7.48%
Driehaus Capital Management, LLC
5.97%
Wellington Management Company, LLP
4.94%
Janus Henderson Investors
4.33%
Other
69.25%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
46.54%
Investment Advisor
30.34%
Hedge Fund
23.10%
Private Equity
1.66%
Venture Capital
1.05%
Sovereign Wealth Fund
0.83%
Research Firm
0.77%
Pension Fund
0.56%
Bank and Trust
0.27%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
416
84.68M
110.35%
+9.65K
2025Q1
434
79.94M
104.19%
-5.23M
2024Q4
434
79.81M
104.31%
-4.80M
2024Q3
425
77.49M
102.39%
-3.82M
2024Q2
431
76.92M
102.03%
-4.12M
2024Q1
421
76.68M
101.81%
-2.76M
2023Q4
404
75.13M
102.42%
+7.65M
2023Q3
386
64.60M
99.41%
-3.93M
2023Q2
377
64.25M
101.09%
-4.03M
2023Q1
347
63.79M
101.12%
-4.16M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Fidelity Management & Research Company LLC
6.16M
8.03%
+73.87K
+1.21%
Mar 31, 2025
Avoro Capital Advisors LLC
5.74M
7.48%
+75.00K
+1.32%
Mar 31, 2025
Driehaus Capital Management, LLC
4.58M
5.97%
+64.26K
+1.42%
Mar 31, 2025
Wellington Management Company, LLP
3.79M
4.94%
+11.59K
+0.31%
Mar 31, 2025
Janus Henderson Investors
3.33M
4.33%
+458.34K
+15.99%
Mar 31, 2025
Capital International Investors
3.09M
4.03%
+541.52K
+21.26%
Mar 31, 2025
Braidwell LP
2.71M
3.53%
-204.09K
-7.00%
Mar 31, 2025
Polar Capital LLP
2.62M
3.42%
-74.62K
-2.77%
Mar 31, 2025
Commodore Capital LP
2.33M
3.03%
-415.00K
-15.15%
Mar 31, 2025
Capital World Investors
2.22M
2.9%
-69.82K
-3.04%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Neuroscience and Healthcare ETF
4.34%
Tema Neuroscience and Mental Health ETF
1.82%
ALPS Medical Breakthroughs ETF
1.62%
Virtus LifeSci Biotech Clinical Trials ETF
0.86%
Goldman Sachs Future Health Care Equity ETF
0.61%
First Trust Multi-Manager Small Cap Opportunities ETF
0.52%
Harbor Health Care ETF
0.42%
BNY Mellon Innovators ETF
0.35%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.34%
iShares Health Innovation Active ETF
0.34%
Ver Mais
iShares Neuroscience and Healthcare ETF
Proporção4.34%
Tema Neuroscience and Mental Health ETF
Proporção1.82%
ALPS Medical Breakthroughs ETF
Proporção1.62%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.86%
Goldman Sachs Future Health Care Equity ETF
Proporção0.61%
First Trust Multi-Manager Small Cap Opportunities ETF
Proporção0.52%
Harbor Health Care ETF
Proporção0.42%
BNY Mellon Innovators ETF
Proporção0.35%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Proporção0.34%
iShares Health Innovation Active ETF
Proporção0.34%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
